New drug combo aims to shrink liver tumors in kidney cancer patients
NCT ID NCT07256223
First seen Dec 04, 2025 · Last updated Apr 25, 2026 · Updated 19 times
Summary
This study tests a combination of two drugs, envafolimab and lenvatinib, as the first treatment for people with a type of kidney cancer (clear cell renal cell carcinoma) that has spread to the liver. The goal is to see if the combination can shrink liver tumors and help patients live longer without the cancer growing. The study will enroll 30 adults who have not had prior cancer treatment and have at least one measurable liver tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER METASTASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.